Lantheus Medical Imaging said yesterday it sold its radiopharmacy and Canadian Gludef manufacturing and distribution businesses to Isologic Radiopharmaceuticals for $9m. As part of the sale, Lantheus and Isologic inked a long-term supply deal which positions Lantheus to supply Isologic with its products on commercial terms, with a set of product purchase commitments included. “We […]
Lantheus Medical Imaging
NuVasive shuffles the deck | Personnel Moves
NuVasive Inc. (NSDQ:NUVA) announced a flurry of new executive assignments yesterday as it reorganizes its leadership team under new CEO Gregory Lucier, who took over the position in May from ousted Alex Lukianov. NuVasive 14-year vet Pat Miles will stay on as COO and president, a position he was appointed to earlier this year, NuVasive said. […]
Lantheus closes $66.7m IPO
Lantheus Medical Imaging said today it closed its $65 million initial public offering after exercising an over-allotment option that netted an estimated $66.7 million in proceeds. The North Billerica, Mass.-based company said it floated 12.3 million shares of stock at $6.00 per share, with 1.4 million shares being sold through an over-allotment option. Credit Suisse Securities, […]
Lantheus prices IPO below range
Lantheus Medical Imaging said yesterday it priced its initial public offering at $6.00 per share, below its previously announced range, for total proceeds of $65 million. The company is offering 10.8 million shares, with an underwriters over-allotment option of another 1.4 million, the North Billerica, Mass.-based company said. Credit Suisse Securities, Jefferies, RBC Capital Markets and […]
Lantheus resuscitates IPO
Lantheus Medical Imaging revived plans for an initial public offering last week, but didn’t set any terms for the flotation.
It’s the 2nd run at the public markets for Billerica, Mass.-based Lantheus, which makes medical imaging isotopes.
Hologic CEO gives glowing review to major stakeholder and activist investor Carl Icahn | Medtech Wall Street news for the week of August 4, 2014
Report: Lantheus spikes IPO plans
Lantheus Medical Imaging reportedly spiked an initial public offering it hoped would raise $125 million, citing "poor market conditions," Renaissance Capital reported.
Lantheus sets terms for IPO
Lantheus Medical Imaging said today that it plans to offer some 9.3 million shares of stock in an initial public offering that could bring in as much as $139 million.
Billerica, Mass.-based Lantheus said it plans to price the offering at $12 to $15 per share, for a range of $111.1 million to $138.9 million.
Lantheus Medical plots IPO worth up to $125M
Massachusetts-based Lantheus Medical Imaging announced today that it filed registration documents ahead of launching an initial public offering.
The company, which makes imaging agents and other diagnostic products, has yet to reveal share pricing or quantity, but set the maximum aggregate offering price at $125 million. Lantheus deals primarily in radiopharmaceutical and contrast agents, according to the prospectus summary.
Lantheus pays $6.2M to settle tax evasion row
Lantheus Medical Imaging signed a settlement with the office of New York Attorney General Eric Schneiderman, agreeing to pay $6.2 million to settle allegations that the company and former parent Bristol-Myers Squibb schemed to avoid paying sales taxes.
Lantheus CFO resigns | Personnel Moves
Lantheus Medical Imaging Inc. finance chief Jeffrey Young resigned from his post, effective August 9. The CFO’s shoes will be filled by interim finance chief John Golubieski, formerly the CFO of Fougera Pharmaceuticals and finance VP at King Pharmaceuticals.